Ranjan Duara, MD
Neurology · Miami Beach, FLNPI 1134159700
Payments from drug & device makers
Across 164 payments — averaging $5124.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$643K
- Eisai Inc.$102K
- Novartis$83K
- Novo Nordisk$8K
- Merck$3K
- Otsuka America Pharmaceutical, Inc.$730
- plus $959 from 10 others
Across 5 payments — averaging $341.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Consulting fees$7,55670%
- Speaking & faculty fees$230%
- Travel & lodging$6296%
- Food & beverage$2,59124%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 28 | $642,671 |
| Eisai Inc. | 41 | $102,313 |
| Novartis | 5 | $82,700 |
| Novo Nordisk | 4 | $8,468 |
| Merck | 2 | $2,539 |
| Otsuka America Pharmaceutical, Inc. | 37 | $730 |
| Lilly USA, LLC | 13 | $338 |
| Corium, LLC | 10 | $130 |
| Idorsia Pharmaceuticals US Inc | 7 | $114 |
| GE HealthCare | 4 | $111 |
| AbbVie | 4 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Acorda Therapeutics, Inc | 2 | $43 |
| Lundbeck LLC | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| C2n Diagnostics, LLC | 1 | $14 |
How this compares
$840,379 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 372 | $44,636 |
| Rivastigmine | 172 | $26,552 |
| MyrbetriqMirabegron | 32 | $24,488 |
| Memantine Hcl ErMemantine Hcl | 272 | $23,233 |
| Memantine Hcl | 514 | $13,118 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $12,572 |
| Quetiapine Fumarate | 299 | $6,866 |
| Sertraline Hcl | 502 | $6,270 |
| Mirtazapine | 261 | $5,443 |
| Donepezil Hcl | 334 | $3,731 |
| Duloxetine Hcl | 88 | $3,542 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 53 | $3,155 |
| Olanzapine | 72 | $3,136 |
| Lamotrigine | 155 | $2,318 |
| Bupropion XlBupropion Hcl | 90 | $2,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric | $88 | $12,57211 claims |
| Lilly USA, LLCOlanzapine | $338 | $3,13672 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Miami Beach
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.